Ventricular Assist Devices Market Finds future growth by Top Players Abiomed, Inc., Asahi Kasei Corporation (Evaheart Medical U.S.A., Inc.), Abbott Laboratories (St. Jude Medical, Inc.), Berlin Heart GmbH

Global Ventricular Assist Devices Market is expected to reach $1,773 million by 2023, growing at a CAGR of 11.8%. Ventricular assist device (VAD) is used to assist a damaged or weakened heart in pumping blood. The device is surgically attached to one or both intact ventricles and thus assists cardiac circulation.

The major factors that contribute to the market growth include technological advancements in ventricular assist devices, awareness among patients about monitoring of the heart, and treatment options for management of cardiac disorders. Moreover, increased presence unmet medical needs in the developing and the under developed regions of the world is anticipated to provide lucrative opportunities for the market growth. However, the main challenge in the market is high cost of the VAD procedure. Also, bleeding complications and other associated risks hamper the growth of the ventricular assist devices market.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/2024

The major companies profiled in the report are
• Abiomed Inc.
• Asahi Kasei Corporation (Evaheart Medical U.S.A. Inc.)
• Abbott Laboratories (St. Jude Medical Inc.)
• Berlin Heart GmbH
• Calon Cardio-Technology Ltd.
• CardiacAssist Technologies
• Jarvik Heart Inc.
• Medtronic plc
• ReliantHeart Inc.
• Terumo Medical Corporation.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/2024

By product, LVADs accounted for the major share of the global ventricular assist devices market in 2016. By application segment, bridge-to-transplant generated the maximum revenue, thus accounting for more than 49% of the global ventricular assist devices market in 2016. In addition, destination therapy segment is expected to witness the highest CAGR of 13.4% during the forecast period. By design, implantable ventricular assist device dominated the market with three-fourths share in the global ventricular assist devices market in 2016.

For More Information @ https://www.alliedmarketresearch.com/purchase-enquiry/2024

Key Findings of the Ventricular Assist Devices Market:
• The left ventricular assist devices (LVADs) segment is projected to grow at a significant CAGR of 11.7%, during the forecast period (2017-2023).
• Transcutaneous ventricular assist device is projected to grow at a significant CAGR, during the forecast period.
• Destination therapy accounted for more than one-fourth share of the global market in 2016.
• Germany and France are the major shareholders, and together accounted for more than one-third share of the European market in 2016.
• Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific market in 2016.

The Asia-Pacific market is projected to grow at the highest CAGR of 14.9% during the forecast period, owing to increase in awareness about the benefits of digital wound measurement devices in healthcare industry and rise in expenditures in emerging markets (such as India and China) to cater to the unmet medical needs.

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/ventricular-assist-devices-market.html

Clients & Testimonials: https://www.alliedmarketresearch.com/testimonials

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.